Cargando…
Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
BACKGROUND: Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally advanced breast cancer or metastatic breast ca...
Autores principales: | Zhao, Qi, Hughes, Rachel, Neupane, Binod, Mickle, Kristin, Su, Yun, Chabot, Isabelle, Betts, Marissa, Kadambi, Ananth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244131/ https://www.ncbi.nlm.nih.gov/pubmed/34193107 http://dx.doi.org/10.1186/s12885-021-08446-8 |
Ejemplares similares
-
Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018) -
Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
por: Tremblay, Gabriel, et al.
Publicado: (2016) -
Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020) -
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021) -
Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer
por: Coe, Faye, et al.
Publicado: (2021)